

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4 Mm 4-30-02

In re application of: Albert R. DiPiero and David G. Sanders

Application No.: 09/990,123

Filed: November 21, 2001

For: HEALTH PLAN MANAGEMENT METHOD AND APPARATUS

INFORMATION DISCLOSURE STATEMENT

TO THE COMMISSIONER FOR PATENTS:

Pursuant to their duty of disclosure, applicants enclose copies of the documents listed on the accompanying Form PTO-1449.

stage, or before the mailing date of the first Office action on the merits, whichever event occurs last. (No statement under 37 (1.97(e) is required.) b.	1.	1. This information disclosure statement is being submitted:								
of either a final action or a notice of allowance. (Check box i. i. A \$240.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is enclosed. ii. A statement specified by 37 CFR 1.97(e) is set forth below. c. After the mailing date of a final action or notice of allowance a or before payment of an issue fee. A statement specified by 3′ 1.97(e) is set forth below. A petition requesting consideration information disclosure statement and the \$130.00 petition fee sin 37 CFR 1.17(i) are enclosed. 2. The attorney or agent signing below hereby states that: each item of information contained in the information disclosure statement was cited in a communication from a foreign patent in a counterpart foreign application not more than three month to the filing of the information disclosure statement. no item of information contained in the information disclosure		a.		application or within three months of the date of entry of the national stage, or before the mailing date of the first Office action on the merits, whichever event occurs last. (No statement under 37 CFR						
submission fee set forth in 37 CFR 1.17(p) is enclosed. ii. A statement specified by 37 CFR 1.97(e) is set forth below. c. After the mailing date of a final action or notice of allowance a or before payment of an issue fee. A statement specified by 3′ 1.97(e) is set forth below. A petition requesting consideration information disclosure statement and the \$130.00 petition fee sin 37 CFR 1.17(i) are enclosed. 2. The attorney or agent signing below hereby states that: each item of information contained in the information disclosure statement was cited in a communication from a foreign patent in a counterpart foreign application not more than three month to the filing of the information disclosure statement. no item of information contained in the information disclosure		b.		After the period set forth in paragraph 1a, but before the mailing date of either a final action or a notice of allowance. (Check box i. or ii.)						
c. After the mailing date of a final action or notice of allowance a or before payment of an issue fee. A statement specified by 3' 1.97(e) is set forth below. A petition requesting consideration information disclosure statement and the \$130.00 petition fee s in 37 CFR 1.17(i) are enclosed. 2. The attorney or agent signing below hereby states that: each item of information contained in the information disclosure statement was cited in a communication from a foreign patent in a counterpart foreign application not more than three month to the filing of the information disclosure statement. no item of information contained in the information disclosure			i.							
or before payment of an issue fee. A statement specified by 3' 1.97(e) is set forth below. A petition requesting consideration information disclosure statement and the \$130.00 petition fee s in 37 CFR 1.17(i) are enclosed. 2.			ii.							
each item of information contained in the information disclosure statement was cited in a communication from a foreign patent in a counterpart foreign application not more than three month to the filing of the information disclosure statement. \[\begin{align*} & & & & & & & & & & & & & & & & & & &		c.		After the mailing date of a final action or notice of allowance and on or before payment of an issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. A petition requesting consideration of the information disclosure statement and the \$130.00 petition fee set forth in 37 CFR 1.17(i) are enclosed.						
statement was cited in a communication from a foreign patent in a counterpart foreign application not more than three month to the filing of the information disclosure statement. no item of information contained in the information disclosure	2.		The attorney or agent signing below hereby states that:							
				each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.						
				no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office						

in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.

3.	Applicant(s) set forth below concise explanations of the relevance of each
	document not in the English language and/or selected document(s) in the
	English language.

By

W. Glen Johnson Registration No. 39,525

April 8th, 2002

STOEL RIVES LLP 900 SW Fifth Avenue, Suite 2600

Portland, Oregon 97204 Telephone: (206) 386-7661 Facsimile: (206) 386-7500

Attorney Docket No.: 40920/1:2

												Sh	eet 1 of 1
FORM PTO-14 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						A	ATTY. DOCKET NO.			APPLICATION NO.		
INFORMATION DISCLOSURE CITATION													
(Use several sheets if necessary)								APPLICANTS					
APR 1 7 2002	FIGE	·						FILING DATE			GROUP		
EXAMINER				_		U.S. PATE	NT DOCUMEN	TS					
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME		CLASS	SUBCLAS I		FILING DATE IF APPROPRIATE	
	AA												
]	FOREIGN PA	TENT DOCUM	ENT	ΓS .				
		DOCUMENT NUMBER				DATE	COUNTRY		CLASS	SUBCLAS		S TRANSLATION YES NO	
	AB												
	- '	OTHE	R DC	CUN	1EN	ITS (Including	Author, Title, I	Date	, Pertinent Pag	es, etc.)		t	·
	AC	AC "Health Grades, The Healthcare Quality Experts", Source: www2.healthgradws.com, printed December 7, 2001, 64 pages											
	AD										nber		
AH "LEXSTAT 26 USC 106", LEXIS Law Publishing, 2001, 7 pages													
AI "LEXSTAT IRC sec. 105", LEXIS Law Publishing, 2000, 8 pages											-		
	AJ Jacob, Julie A., "Some insurers embracing defined contribution plans", amednews.com, March 12, 2001, 4 pages											h 12,	
AK "Myhealthbank names two to management team", The Business Journal, Portland, June 2000, 2 pages										2			
AL									E	2F	CFIV	ED	
	AM	RECEIVED											
AN APR 2 2 APR 2 APR 2 2 APR 2 A								Ai	 	1010C			
								logy Cen	ter 210				
	AP			_									
EXAMINER									DATE CONS	SIDERE	D		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.